Sanofi (NYSE:SNY) was upgraded by equities researchers at UBS Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, The Fly reports.
A number of other equities analysts have also commented on the stock. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Friday, June 21st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Tuesday, August 6th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $51.00.
Shares of NYSE:SNY opened at $42.10 on Wednesday. The firm has a market capitalization of $103.37 billion, a price-to-earnings ratio of 13.45, a PEG ratio of 2.41 and a beta of 0.67. The business’s fifty day simple moving average is $42.29. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. Sanofi has a 52 week low of $40.00 and a 52 week high of $45.62.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 29th. The company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.07. The company had revenue of $8.63 billion for the quarter, compared to analyst estimates of $8.42 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. Sanofi’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.25 earnings per share. Research analysts anticipate that Sanofi will post 3.1 earnings per share for the current fiscal year.
In other news, major shareholder Sanofi bought 93,750 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was acquired at an average price of $16.00 per share, with a total value of $1,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ibex Wealth Advisors bought a new stake in Sanofi in the second quarter valued at $25,000. Heritage Wealth Advisors increased its stake in Sanofi by 141.2% in the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after purchasing an additional 353 shares in the last quarter. Bessemer Group Inc. increased its stake in Sanofi by 292.4% in the second quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Nkcfo LLC bought a new stake in Sanofi in the first quarter valued at $35,000. Finally, Cullen Frost Bankers Inc. bought a new stake in Sanofi in the first quarter valued at $35,000. 7.04% of the stock is owned by institutional investors and hedge funds.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.